Injective secures Nasdaq ETF approval: INJ gains momentum
Injective (INJ) is trading at $8.01, up 8.02% on the day. The asset currently sits above its key moving averages, reflecting continued upward momentum within the session.
Highlights
- Nasdaq approved the listing of Canary Capital's Injective ETF, making INJ available as a regulated exchange-traded product in the United States.
- This ETF provides institutional and traditional investors with regulated access to Injective, which could expand INJ's investor base and liquidity.
- INJ trades with a bullish technical structure, a projected price range of $7.28 to $8.29, and high probability of an upward move.
ETF listing approval as institutional access expands demand for INJ
Nasdaq has approved the listing of Canary Capital's Injective ETF, marking the first time INJ will be available as a regulated exchange-traded product in the United States, according to TradingView. This development is significant as it provides institutional and traditional investors with a new, regulated avenue to access Injective, potentially broadening the investor base and increasing market liquidity. The ETF approval is likely to drive additional demand for INJ, underscoring the asset's growing relevance in mainstream financial markets.
Bullish momentum confirmed as technicals align above major supports
INJ/USD is trading above the MA-20 at $7.87, the MA-50 at $7.5, and the MA-200 at $5.59. The Ichimoku Kijun at $7.61 acts as immediate support. MACD signals strong buy momentum, with ADX confirming a bullish tone. RSI and CCI are neutral, while Stochastic RSI is in the oversold zone, suggesting a possible short-term rebound. Bull/Bear Power is slightly positive at 0.12, indicating continued intraday buyer strength. The Awesome Oscillator remains neutral.
Upside breakout likely as volatility persists with strong support
Over the next 2–3 trading days, INJ is expected to trade between $7.28 and $8.29, consistent with its typical volatility band relative to current levels. The probability of an upward move is very high; a break above resistance could open further upside potential. Conversely, a move below $7.28 would break support and could lead to short-term selling pressure, though this scenario is considered unlikely.
Previously it was reported that Nasdaq's approval of Canary Capital's Injective ETF signaled heightened institutional interest and a potential expansion of INJ's investor base. The present technical setup, along with the ETF's introduction as a regulated product, reinforces Injective's bullish outlook, making any sustained move above immediate resistance an important trigger for additional upside.